Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 4
2020 4
2021 2
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Erratum on "Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation".
Cacemiro MDC, Cominal JG, Tognon R, Nunes NS, Simões BP, Lôbo de Figueiredo-Pontes L, Bazzo Catto LF, Traina F, Xisto Souto E, Albani Zambuzi F, Frantz FG, de Castro FA. Cacemiro MDC, et al. Hematol Transfus Cell Ther. 2021 Jan-Mar;43(1):117. doi: 10.1016/j.htct.2020.11.001. Epub 2020 Nov 25. Hematol Transfus Cell Ther. 2021. PMID: 33531280 Free PMC article. No abstract available.
Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Cominal JG, Cacemiro MDC, Berzoti-Coelho MG, Pereira IEG, Frantz FG, Souto EX, Covas DT, de Figueiredo-Pontes LL, Oliveira MC, Malmegrim KCR, de Castro FA. Cominal JG, et al. Among authors: cacemiro mdc. Front Oncol. 2021 May 18;11:665037. doi: 10.3389/fonc.2021.665037. eCollection 2021. Front Oncol. 2021. PMID: 34084749 Free PMC article.
Bioactive Lipids as Chronic Myeloid Leukemia's Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors.
de Almeida FC, Berzoti-Coelho MG, Toro DM, Cacemiro MDC, Bassan VL, Barretto GD, Garibaldi PMM, Palma LC, de Figueiredo-Pontes LL, Sorgi CA, Faciolli LH, Gardinassi LG, de Castro FA. de Almeida FC, et al. Among authors: cacemiro mdc. Front Immunol. 2022 Apr 13;13:840173. doi: 10.3389/fimmu.2022.840173. eCollection 2022. Front Immunol. 2022. PMID: 35493444 Free PMC article.
Bothrops moojeni L-amino acid oxidase induces apoptosis and epigenetic modulation on Bcr-Abl+ cells.
Burin SM, Cacemiro MDC, Cominal JG, Grandis RA, Machado ART, Donaires FS, Cintra ACO, Ambrosio L, Antunes LMG, Sampaio SV, de Castro FA. Burin SM, et al. Among authors: cacemiro mdc. J Venom Anim Toxins Incl Trop Dis. 2020 Dec 14;26:e20200123. doi: 10.1590/1678-9199-JVATITD-2020-0123. J Venom Anim Toxins Incl Trop Dis. 2020. PMID: 33354202 Free PMC article.
Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN.
Benlabiod C, Cacemiro MDC, Nédélec A, Edmond V, Muller D, Rameau P, Touchard L, Gonin P, Constantinescu SN, Raslova H, Villeval JL, Vainchenker W, Plo I, Marty C. Benlabiod C, et al. Among authors: cacemiro mdc. Nat Commun. 2020 Sep 28;11(1):4886. doi: 10.1038/s41467-020-18691-3. Nat Commun. 2020. PMID: 32985500 Free PMC article.
MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia.
Rabello DDA, Ferreira VDDS, Berzoti-Coelho MG, Burin SM, Magro CL, Cacemiro MDC, Simões BP, Saldanha-Araujo F, de Castro FA, Pittella-Silva F. Rabello DDA, et al. Among authors: cacemiro mdc. Cancer Cell Int. 2018 Feb 20;18:26. doi: 10.1186/s12935-018-0523-1. eCollection 2018. Cancer Cell Int. 2018. PMID: 29483845 Free PMC article.
11 results